Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 1999

View Archived Issues

New approach to inhibiting thrombin-induced neuronal cell death

Vagus nerve stimulation offers new possibilities for the treatment of depression

Preliminary results reported for Biojector 2000-delivered malaria vaccine

Biomira's BLP25 liposome technology offers promise as cancer therapy

MGH team identifies TSP-2 as a novel endogenous antiangiogenic factor

Immune Network Research reacquires 1F7 AIDS antibody

Genome Therapeutics initiates osteoporosis genomics alliance with Wyeth-Ayerst

Millennium validates prostate cancer gene target as part of Lilly collaboration

NPS and Allelix finalize merger

Nycomed Amersham files for E.U. approval of ultrasound imaging agent

Schwarz adds new anticonvulsant to R&D portfolio

Impressive early phase II clinical data reported for OvaRex in relapsed ovarian cancer

Cel-Sci completes another study in head and neck cancer

BIM-46068: a pseudopeptide FTase inhibitor with promise for cancer Rx

Interneuron licenses worldwide rights to pagoclone to Warner-Lambert

Salix responds to FDA approvable letter and reacquires rights to UC treatment from AstraZeneca

Agents for accelerating peristalsis in development at Dainippon

New series of selectin inhibitors patented by Sumitomo

Mitsui presents differentiation-inducing agents

ADIR discloses new melatonergic agents with cyclic structure

Antiangiogenic fumagillin analogues in the pipeline at BioChem Pharma

BMS presents new water-soluble triazole antifungal prodrugs with superior properties

Pharmacological profile of SR-141716A, a selective CB1 antagonist, further characterized

Citicoline Stroke Study Group trial does not show benefit for citicoline in overall study population

Aventis receives first product approval: E.U. grants approval of Synercid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...